Pfizer (PFE) Goodwill & Intangibles (2009 - 2026)

Pfizer (PFE) has 18 years of Goodwill & Intangibles data on file, last reported at $124.0 billion in Q1 2026.

• Goodwill & Intangibles for Q1 2026 came in at $124.0 billion, up 1.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $124.0 billion (up 1.26% YoY), and the FY2025 annual result was $125.0 billion, up 0.85% from the prior year.
• Goodwill & Intangibles retreated to $124.0 billion in Q1 2026 per PFE's latest filing, from $125.0 billion in the prior quarter.
• Over five years, Goodwill & Intangibles peaked at $132.7 billion in Q4 2023 and troughed at $77.6 billion in Q4 2022.
• A 5-year average of $110.0 billion and a median of $121.7 billion in 2025 frame the typical range for Goodwill & Intangibles.
• The sharpest annual moves came in 2024 and 2025: Goodwill & Intangibles surged 41.34% in 2024, then dropped 7.35% in 2025.
• A 5-year view of Goodwill & Intangibles shows it stood at $94.7 billion in 2022, then jumped by 40.04% to $132.7 billion in 2023, then declined by 6.59% to $123.9 billion in 2024, then advanced by 0.85% to $125.0 billion in 2025, then slipped by 0.82% to $124.0 billion in 2026.
• Business Quant data shows PFE's Goodwill & Intangibles at $124.0 billion in Q1 2026, $125.0 billion in Q4 2025, and $120.4 billion in Q3 2025.